t(14;18) translocation: A predictive blood biomarker for follicular lymphoma

Sandrine Roulland, Rachel S. Kelly, Ester Morgado, Stéphanie Sungalee, Philippe Solal-Celigny, Philippe Colombat, Nathalie Jouve, Domenico Palli, Valeria Pala, Rosario Tumino, Salvatore Panico, Carlotta Sacerdote, José R. Quirós, Carlos A. Gonzáles, Maria José Sánchez, Miren Dorronsoro, Carmen Navarro, Aurelio Barricarte, Anne Tjønneland, Anja OlsenKim Overvad, Federico Canzian, Rudolf Kaaks, Heiner Boeing, Dagmar Drogan, Alexandra Nieters, Françoise Clavel-Chapelon, Antonia Trichopoulou, Dimitrios Trichopoulos, Pagona Lagiou, H. Bas Bueno-de-Mesquita, Petra H M Peeters, Roel Vermeulen, Göran Hallmans, Beatrice Melin, Signe Borgquist, Joyce Carlson, Eiliv Lund, Elisabete Weiderpass, Kay Tee Khaw, Nick Wareham, Timothy J. Key, Ruth C. Travis, Pietro Ferrari, Isabelle Romieu, Elio Riboli, Gilles Salles, Paolo Vineis, Bertrand Nadel

Research output: Contribution to journalArticle

Abstract

Purpose: The (14;18) translocation constitutes both a genetic hallmark and critical early event in the natural history of follicular lymphoma (FL). However, t(14;18) is also detectable in the blood of otherwise healthy persons, and its relationship with progression to disease remains unclear. Here we sought to determine whether t(14;18)-positive cells in healthy individuals represent tumor precursors and whether their detection could be used as an early predictor for FL. Participants and Methods: Among 520,000 healthy participants enrolled onto the EPIC (European Prospective Investigation Into Cancer and Nutrition) cohort, we identified 100 who developed FL 2 to 161 months after enrollment. Prediagnostic blood from these and 218 controls were screened for t(14;18) using sensitive polymerase chain reaction-based assays. Results were subsequently validated in an independent cohort (65 case participants; 128 controls). Clonal relationships between t(14;18) cells and FL were also assessed by molecular backtracking of paired prediagnostic blood and tumor samples. Results: Clonal analysis of t(14;18) junctions in paired prediagnostic blood versus tumor samples demonstrated that progression to FL occurred from t(14;18)-positive committed precursors. Furthermore, healthy participants at enrollment who developed FL up to 15 years later showed a markedly higher t(14;18) prevalence and frequency than controls (P <.001). Altogether, we estimated a 23-fold higher risk of subsequent FL in blood samples associated with a frequency > 10-4 (odds ratio, 23.17; 95% CI, 9.98 to 67.31; P <.001). Remarkably, risk estimates remained high and significant up to 15 years before diagnosis. Conclusion: High t(14;18) frequency in blood from healthy individuals defines the first predictive biomarker for FL, effective years before diagnosis.

Original languageEnglish
Pages (from-to)1347-1355
Number of pages9
JournalJournal of Clinical Oncology
Volume32
Issue number13
DOIs
Publication statusPublished - May 1 2014

Fingerprint

Follicular Lymphoma
Biomarkers
Neoplasms
Healthy Volunteers
Disease Progression
Odds Ratio
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Roulland, S., Kelly, R. S., Morgado, E., Sungalee, S., Solal-Celigny, P., Colombat, P., ... Nadel, B. (2014). t(14;18) translocation: A predictive blood biomarker for follicular lymphoma. Journal of Clinical Oncology, 32(13), 1347-1355. https://doi.org/10.1200/JCO.2013.52.8190

t(14;18) translocation : A predictive blood biomarker for follicular lymphoma. / Roulland, Sandrine; Kelly, Rachel S.; Morgado, Ester; Sungalee, Stéphanie; Solal-Celigny, Philippe; Colombat, Philippe; Jouve, Nathalie; Palli, Domenico; Pala, Valeria; Tumino, Rosario; Panico, Salvatore; Sacerdote, Carlotta; Quirós, José R.; Gonzáles, Carlos A.; Sánchez, Maria José; Dorronsoro, Miren; Navarro, Carmen; Barricarte, Aurelio; Tjønneland, Anne; Olsen, Anja; Overvad, Kim; Canzian, Federico; Kaaks, Rudolf; Boeing, Heiner; Drogan, Dagmar; Nieters, Alexandra; Clavel-Chapelon, Françoise; Trichopoulou, Antonia; Trichopoulos, Dimitrios; Lagiou, Pagona; Bueno-de-Mesquita, H. Bas; Peeters, Petra H M; Vermeulen, Roel; Hallmans, Göran; Melin, Beatrice; Borgquist, Signe; Carlson, Joyce; Lund, Eiliv; Weiderpass, Elisabete; Khaw, Kay Tee; Wareham, Nick; Key, Timothy J.; Travis, Ruth C.; Ferrari, Pietro; Romieu, Isabelle; Riboli, Elio; Salles, Gilles; Vineis, Paolo; Nadel, Bertrand.

In: Journal of Clinical Oncology, Vol. 32, No. 13, 01.05.2014, p. 1347-1355.

Research output: Contribution to journalArticle

Roulland, S, Kelly, RS, Morgado, E, Sungalee, S, Solal-Celigny, P, Colombat, P, Jouve, N, Palli, D, Pala, V, Tumino, R, Panico, S, Sacerdote, C, Quirós, JR, Gonzáles, CA, Sánchez, MJ, Dorronsoro, M, Navarro, C, Barricarte, A, Tjønneland, A, Olsen, A, Overvad, K, Canzian, F, Kaaks, R, Boeing, H, Drogan, D, Nieters, A, Clavel-Chapelon, F, Trichopoulou, A, Trichopoulos, D, Lagiou, P, Bueno-de-Mesquita, HB, Peeters, PHM, Vermeulen, R, Hallmans, G, Melin, B, Borgquist, S, Carlson, J, Lund, E, Weiderpass, E, Khaw, KT, Wareham, N, Key, TJ, Travis, RC, Ferrari, P, Romieu, I, Riboli, E, Salles, G, Vineis, P & Nadel, B 2014, 't(14;18) translocation: A predictive blood biomarker for follicular lymphoma', Journal of Clinical Oncology, vol. 32, no. 13, pp. 1347-1355. https://doi.org/10.1200/JCO.2013.52.8190
Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P et al. t(14;18) translocation: A predictive blood biomarker for follicular lymphoma. Journal of Clinical Oncology. 2014 May 1;32(13):1347-1355. https://doi.org/10.1200/JCO.2013.52.8190
Roulland, Sandrine ; Kelly, Rachel S. ; Morgado, Ester ; Sungalee, Stéphanie ; Solal-Celigny, Philippe ; Colombat, Philippe ; Jouve, Nathalie ; Palli, Domenico ; Pala, Valeria ; Tumino, Rosario ; Panico, Salvatore ; Sacerdote, Carlotta ; Quirós, José R. ; Gonzáles, Carlos A. ; Sánchez, Maria José ; Dorronsoro, Miren ; Navarro, Carmen ; Barricarte, Aurelio ; Tjønneland, Anne ; Olsen, Anja ; Overvad, Kim ; Canzian, Federico ; Kaaks, Rudolf ; Boeing, Heiner ; Drogan, Dagmar ; Nieters, Alexandra ; Clavel-Chapelon, Françoise ; Trichopoulou, Antonia ; Trichopoulos, Dimitrios ; Lagiou, Pagona ; Bueno-de-Mesquita, H. Bas ; Peeters, Petra H M ; Vermeulen, Roel ; Hallmans, Göran ; Melin, Beatrice ; Borgquist, Signe ; Carlson, Joyce ; Lund, Eiliv ; Weiderpass, Elisabete ; Khaw, Kay Tee ; Wareham, Nick ; Key, Timothy J. ; Travis, Ruth C. ; Ferrari, Pietro ; Romieu, Isabelle ; Riboli, Elio ; Salles, Gilles ; Vineis, Paolo ; Nadel, Bertrand. / t(14;18) translocation : A predictive blood biomarker for follicular lymphoma. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 13. pp. 1347-1355.
@article{6370bdf55f7547d3b8b70152bc8daf63,
title = "t(14;18) translocation: A predictive blood biomarker for follicular lymphoma",
abstract = "Purpose: The (14;18) translocation constitutes both a genetic hallmark and critical early event in the natural history of follicular lymphoma (FL). However, t(14;18) is also detectable in the blood of otherwise healthy persons, and its relationship with progression to disease remains unclear. Here we sought to determine whether t(14;18)-positive cells in healthy individuals represent tumor precursors and whether their detection could be used as an early predictor for FL. Participants and Methods: Among 520,000 healthy participants enrolled onto the EPIC (European Prospective Investigation Into Cancer and Nutrition) cohort, we identified 100 who developed FL 2 to 161 months after enrollment. Prediagnostic blood from these and 218 controls were screened for t(14;18) using sensitive polymerase chain reaction-based assays. Results were subsequently validated in an independent cohort (65 case participants; 128 controls). Clonal relationships between t(14;18) cells and FL were also assessed by molecular backtracking of paired prediagnostic blood and tumor samples. Results: Clonal analysis of t(14;18) junctions in paired prediagnostic blood versus tumor samples demonstrated that progression to FL occurred from t(14;18)-positive committed precursors. Furthermore, healthy participants at enrollment who developed FL up to 15 years later showed a markedly higher t(14;18) prevalence and frequency than controls (P <.001). Altogether, we estimated a 23-fold higher risk of subsequent FL in blood samples associated with a frequency > 10-4 (odds ratio, 23.17; 95{\%} CI, 9.98 to 67.31; P <.001). Remarkably, risk estimates remained high and significant up to 15 years before diagnosis. Conclusion: High t(14;18) frequency in blood from healthy individuals defines the first predictive biomarker for FL, effective years before diagnosis.",
author = "Sandrine Roulland and Kelly, {Rachel S.} and Ester Morgado and St{\'e}phanie Sungalee and Philippe Solal-Celigny and Philippe Colombat and Nathalie Jouve and Domenico Palli and Valeria Pala and Rosario Tumino and Salvatore Panico and Carlotta Sacerdote and Quir{\'o}s, {Jos{\'e} R.} and Gonz{\'a}les, {Carlos A.} and S{\'a}nchez, {Maria Jos{\'e}} and Miren Dorronsoro and Carmen Navarro and Aurelio Barricarte and Anne Tj{\o}nneland and Anja Olsen and Kim Overvad and Federico Canzian and Rudolf Kaaks and Heiner Boeing and Dagmar Drogan and Alexandra Nieters and Fran{\cc}oise Clavel-Chapelon and Antonia Trichopoulou and Dimitrios Trichopoulos and Pagona Lagiou and Bueno-de-Mesquita, {H. Bas} and Peeters, {Petra H M} and Roel Vermeulen and G{\"o}ran Hallmans and Beatrice Melin and Signe Borgquist and Joyce Carlson and Eiliv Lund and Elisabete Weiderpass and Khaw, {Kay Tee} and Nick Wareham and Key, {Timothy J.} and Travis, {Ruth C.} and Pietro Ferrari and Isabelle Romieu and Elio Riboli and Gilles Salles and Paolo Vineis and Bertrand Nadel",
year = "2014",
month = "5",
day = "1",
doi = "10.1200/JCO.2013.52.8190",
language = "English",
volume = "32",
pages = "1347--1355",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - t(14;18) translocation

T2 - A predictive blood biomarker for follicular lymphoma

AU - Roulland, Sandrine

AU - Kelly, Rachel S.

AU - Morgado, Ester

AU - Sungalee, Stéphanie

AU - Solal-Celigny, Philippe

AU - Colombat, Philippe

AU - Jouve, Nathalie

AU - Palli, Domenico

AU - Pala, Valeria

AU - Tumino, Rosario

AU - Panico, Salvatore

AU - Sacerdote, Carlotta

AU - Quirós, José R.

AU - Gonzáles, Carlos A.

AU - Sánchez, Maria José

AU - Dorronsoro, Miren

AU - Navarro, Carmen

AU - Barricarte, Aurelio

AU - Tjønneland, Anne

AU - Olsen, Anja

AU - Overvad, Kim

AU - Canzian, Federico

AU - Kaaks, Rudolf

AU - Boeing, Heiner

AU - Drogan, Dagmar

AU - Nieters, Alexandra

AU - Clavel-Chapelon, Françoise

AU - Trichopoulou, Antonia

AU - Trichopoulos, Dimitrios

AU - Lagiou, Pagona

AU - Bueno-de-Mesquita, H. Bas

AU - Peeters, Petra H M

AU - Vermeulen, Roel

AU - Hallmans, Göran

AU - Melin, Beatrice

AU - Borgquist, Signe

AU - Carlson, Joyce

AU - Lund, Eiliv

AU - Weiderpass, Elisabete

AU - Khaw, Kay Tee

AU - Wareham, Nick

AU - Key, Timothy J.

AU - Travis, Ruth C.

AU - Ferrari, Pietro

AU - Romieu, Isabelle

AU - Riboli, Elio

AU - Salles, Gilles

AU - Vineis, Paolo

AU - Nadel, Bertrand

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Purpose: The (14;18) translocation constitutes both a genetic hallmark and critical early event in the natural history of follicular lymphoma (FL). However, t(14;18) is also detectable in the blood of otherwise healthy persons, and its relationship with progression to disease remains unclear. Here we sought to determine whether t(14;18)-positive cells in healthy individuals represent tumor precursors and whether their detection could be used as an early predictor for FL. Participants and Methods: Among 520,000 healthy participants enrolled onto the EPIC (European Prospective Investigation Into Cancer and Nutrition) cohort, we identified 100 who developed FL 2 to 161 months after enrollment. Prediagnostic blood from these and 218 controls were screened for t(14;18) using sensitive polymerase chain reaction-based assays. Results were subsequently validated in an independent cohort (65 case participants; 128 controls). Clonal relationships between t(14;18) cells and FL were also assessed by molecular backtracking of paired prediagnostic blood and tumor samples. Results: Clonal analysis of t(14;18) junctions in paired prediagnostic blood versus tumor samples demonstrated that progression to FL occurred from t(14;18)-positive committed precursors. Furthermore, healthy participants at enrollment who developed FL up to 15 years later showed a markedly higher t(14;18) prevalence and frequency than controls (P <.001). Altogether, we estimated a 23-fold higher risk of subsequent FL in blood samples associated with a frequency > 10-4 (odds ratio, 23.17; 95% CI, 9.98 to 67.31; P <.001). Remarkably, risk estimates remained high and significant up to 15 years before diagnosis. Conclusion: High t(14;18) frequency in blood from healthy individuals defines the first predictive biomarker for FL, effective years before diagnosis.

AB - Purpose: The (14;18) translocation constitutes both a genetic hallmark and critical early event in the natural history of follicular lymphoma (FL). However, t(14;18) is also detectable in the blood of otherwise healthy persons, and its relationship with progression to disease remains unclear. Here we sought to determine whether t(14;18)-positive cells in healthy individuals represent tumor precursors and whether their detection could be used as an early predictor for FL. Participants and Methods: Among 520,000 healthy participants enrolled onto the EPIC (European Prospective Investigation Into Cancer and Nutrition) cohort, we identified 100 who developed FL 2 to 161 months after enrollment. Prediagnostic blood from these and 218 controls were screened for t(14;18) using sensitive polymerase chain reaction-based assays. Results were subsequently validated in an independent cohort (65 case participants; 128 controls). Clonal relationships between t(14;18) cells and FL were also assessed by molecular backtracking of paired prediagnostic blood and tumor samples. Results: Clonal analysis of t(14;18) junctions in paired prediagnostic blood versus tumor samples demonstrated that progression to FL occurred from t(14;18)-positive committed precursors. Furthermore, healthy participants at enrollment who developed FL up to 15 years later showed a markedly higher t(14;18) prevalence and frequency than controls (P <.001). Altogether, we estimated a 23-fold higher risk of subsequent FL in blood samples associated with a frequency > 10-4 (odds ratio, 23.17; 95% CI, 9.98 to 67.31; P <.001). Remarkably, risk estimates remained high and significant up to 15 years before diagnosis. Conclusion: High t(14;18) frequency in blood from healthy individuals defines the first predictive biomarker for FL, effective years before diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=84902684758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902684758&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.52.8190

DO - 10.1200/JCO.2013.52.8190

M3 - Article

C2 - 24687831

AN - SCOPUS:84902684758

VL - 32

SP - 1347

EP - 1355

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -